DrugPatentWatch Database Preview
Uridine triacetate - Generic Drug Details
What are the generic drug sources for uridine triacetate and what is the scope of freedom to operate?
Uridine triacetate
is the generic ingredient in two branded drugs marketed by Wellstat Therap and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Uridine triacetate has one hundred and seventy-five patent family members in twenty-one countries.
There are thirty-six drug master file entries for uridine triacetate. One supplier is listed for this compound.
Summary for uridine triacetate
| International Patents: | 175 |
| US Patents: | 2 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 36 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 55 |
| Clinical Trials: | 2 |
| Patent Applications: | 99 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | uridine triacetate at DailyMed |
Recent Clinical Trials for uridine triacetate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wellstat Therapeutics | Phase 2 |
| Wellstat Therapeutics | N/A |
Pharmacology for uridine triacetate
| Ingredient-type | Pyrimidines Analogs/Derivatives |
| Drug Class | Pyrimidine Analog |
Synonyms for uridine triacetate
| (2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE |
| [(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate |
| [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate |
| 105T388 |
| 2 ,3 ,5 -Triacetyluridine |
| 2',3',5'-Tri-O-acetyluridine |
| 2',3',5'-Tri-O-acetyluridine, >=98% |
| 293738-13-3 |
| 2WP61F175M |
| 4105-38-8 |
| AC1L2FGB |
| AK-73070 |
| AKOS015964563 |
| AN-158 |
| ANW-29551 |
| API0001026 |
| AUFUWRKPQLGTGF-FMKGYKFTSA-N |
| AX8007900 |
| CHEBI:90914 |
| CHEMBL2107381 |
| CTK3J5861 |
| D09985 |
| DB09144 |
| EINECS 223-881-5 |
| FT-0081134 |
| J-700012 |
| KSC495Q6D |
| MFCD00023795 |
| MLS006009982 |
| MolPort-005-940-324 |
| PN 401 |
| PN401 |
| PubChem14176 |
| RG 2133 |
| SB18970 |
| SCHEMBL871011 |
| SMR004701034 |
| Tri-O-acetyluridine |
| triacetyl uridine |
| Triacetyluridine |
| UNII-2WP61F175M |
| URI007 |
| Uridine 2',3',5'-triacetate |
| Uridine triacetate (USAN/INN) |
| Uridine triacetate [USAN:INN] |
| Uridine, 2',3',5'-triacetate |
| Vistogard |
| Vistonuridine |
| Xuriden |
| Xuriden (TN) |
| ZINC3843198 |
US Patents and Regulatory Information for uridine triacetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for uridine triacetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for uridine triacetate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2203669 | Start Trial |
| China | 1089239 | Start Trial |
| Australia | 663309 | Start Trial |
| Hong Kong | 1072897 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for uridine triacetate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1849470 | LUC00036 | Luxembourg | Start Trial | PRODUCT NAME: TRIFLURIDINE COMBINEE AU TIPIRACIL OU UN SEL DE TIPIRACIL TEL QUE L'HYDROCHLORURE DE TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427 |
| 1849470 | CA 2017 00036 | Denmark | Start Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427 |
| 1849470 | 1790063-0 | Sweden | Start Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1096 20160427 |
| 1849470 | 2017/033 | Ireland | Start Trial | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.